Glaxo's Ceptaz (ceftazidime)
Executive Summary
New L-arginine formulation of the injectable, broad-spectrum antibiotic Fortaz approved Sept. 27. The firm will continue to market Fortaz, and plans to launch Ceptaz "as soon as possible." The product was "approvable" as of June 4 ("The Pink Sheet" Aug. 20, T&G-1). Glaxo submitted the Ceptaz NDA in the spring of 1989.
You may also be interested in...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: